JP7317038B2 - がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 - Google Patents

がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 Download PDF

Info

Publication number
JP7317038B2
JP7317038B2 JP2020552260A JP2020552260A JP7317038B2 JP 7317038 B2 JP7317038 B2 JP 7317038B2 JP 2020552260 A JP2020552260 A JP 2020552260A JP 2020552260 A JP2020552260 A JP 2020552260A JP 7317038 B2 JP7317038 B2 JP 7317038B2
Authority
JP
Japan
Prior art keywords
cbz
pebca
nps
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020552260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519323A (ja
Inventor
イール モルク,
ルス シュミット,
アイナル スルハイム,
ペール ステンスタッド,
ハイディ ヨンセン,
キルステン サンドヴィグ,
グンヒルド メランズモ,
トーレ スコットランド,
シャスティ フラットマルク,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SINTEF TTO AS
Original Assignee
SINTEF TTO AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SINTEF TTO AS filed Critical SINTEF TTO AS
Publication of JP2021519323A publication Critical patent/JP2021519323A/ja
Application granted granted Critical
Publication of JP7317038B2 publication Critical patent/JP7317038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020552260A 2018-03-27 2019-03-27 がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 Active JP7317038B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180429 2018-03-27
NO20180429 2018-03-27
PCT/EP2019/057678 WO2019185685A1 (en) 2018-03-27 2019-03-27 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Publications (2)

Publication Number Publication Date
JP2021519323A JP2021519323A (ja) 2021-08-10
JP7317038B2 true JP7317038B2 (ja) 2023-07-28

Family

ID=66049182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020552260A Active JP7317038B2 (ja) 2018-03-27 2019-03-27 がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子
JP2021560300A Active JP7550167B2 (ja) 2018-03-27 2019-09-26 がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021560300A Active JP7550167B2 (ja) 2018-03-27 2019-09-26 がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子

Country Status (8)

Country Link
US (3) US20210113482A1 (cg-RX-API-DMAC7.html)
EP (2) EP3773471A1 (cg-RX-API-DMAC7.html)
JP (2) JP7317038B2 (cg-RX-API-DMAC7.html)
CN (2) CN111989087A (cg-RX-API-DMAC7.html)
AU (1) AU2019437385B2 (cg-RX-API-DMAC7.html)
BR (2) BR112020019452A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134923A1 (cg-RX-API-DMAC7.html)
WO (2) WO2019185685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer
CN111989087A (zh) 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
JP7461932B2 (ja) * 2018-08-23 2024-04-04 シンテフ ティーティーオー エイエス ナノ粒子
KR20230031188A (ko) * 2020-02-26 2023-03-07 바이오써젠 에이에스 치료적 폴리엔 마크롤리드의 제약 조성물 및 그의 사용 방법
GB202501169D0 (en) 2025-01-27 2025-03-12 Sintef Tto As Methods of producing polymeric particles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541462A (ja) 2006-07-04 2009-11-26 ナノデル テクノロジーズ ゲーエムベーハー 2工程ミニエマルジョン法
JP2016520606A (ja) 2013-05-28 2016-07-14 シンテフ ティーティーオー アクティーゼルスカブ ステルスナノ粒子を調製するためのプロセス
CN107115532A (zh) 2016-02-24 2017-09-01 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872703B1 (fr) 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
JP2008542293A (ja) 2005-05-23 2008-11-27 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 超音波増強ナノ粒子媒介性薬物送達のためのエコー形成性マイクロバブルおよびマイクロエマルジョン
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
FR2921660B1 (fr) 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
ES2424476T3 (es) 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
US20150343079A1 (en) 2012-10-25 2015-12-03 Sogang University Research Foundation Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
US10391185B2 (en) 2014-11-26 2019-08-27 Fujifilm Visualsonics, Inc. Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles
WO2016134115A1 (en) 2015-02-20 2016-08-25 Trustees Of Boston University Theranostic compositions and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US20170071866A1 (en) * 2015-09-14 2017-03-16 Onxeo S.A. Nanoparticles loaded with active ingredients, their process of preparation, and their uses
WO2017046037A1 (en) * 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
US10980826B2 (en) * 2015-11-06 2021-04-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR102803158B1 (ko) * 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
KR20170133257A (ko) 2016-05-24 2017-12-05 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
EP3518900A1 (en) 2016-09-29 2019-08-07 Sintef TTO AS A new drug delivery system for treatment of disease
NO342271B1 (en) 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
CN111989087A (zh) * 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541462A (ja) 2006-07-04 2009-11-26 ナノデル テクノロジーズ ゲーエムベーハー 2工程ミニエマルジョン法
JP2016520606A (ja) 2013-05-28 2016-07-14 シンテフ ティーティーオー アクティーゼルスカブ ステルスナノ粒子を調製するためのプロセス
CN107115532A (zh) 2016-02-24 2017-09-01 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bulg. J. Chem.,2012年,Vol. 1, No. 2,pp. 61-73
Ultrasound in Med. & Biol.,2017年,Vol. 43, No. 11,pp. 2651-2669

Also Published As

Publication number Publication date
BR112020019452A2 (pt) 2021-01-05
JP7550167B2 (ja) 2024-09-12
US20200061019A1 (en) 2020-02-27
EP3946253A1 (en) 2022-02-09
CN111989087A (zh) 2020-11-24
WO2019185685A1 (en) 2019-10-03
US11806330B2 (en) 2023-11-07
EP3773471A1 (en) 2021-02-17
US20190298682A1 (en) 2019-10-03
AU2019437385A1 (en) 2021-11-04
AU2019437385B2 (en) 2025-04-10
JP2022527858A (ja) 2022-06-06
WO2020192950A1 (en) 2020-10-01
US20210113482A1 (en) 2021-04-22
CA3134923A1 (en) 2020-10-01
CN113840594A (zh) 2021-12-24
JP2021519323A (ja) 2021-08-10
BR112021019003A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
Fusser et al. Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
Albuquerque et al. pH-responsive polymersome-mediated delivery of doxorubicin into tumor sites enhances the therapeutic efficacy and reduces cardiotoxic effects
Chen et al. Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles
Yang et al. Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer
Song et al. Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers
Liu et al. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles
Cho et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin
Danhier et al. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors
US20210113482A1 (en) Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer
Sun et al. Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel
Yuan et al. A novel self‐assembly albumin nanocarrier for reducing doxorubicin‐mediated cardiotoxicity
CN108938594B (zh) 一种药物复合物及其制备方法与应用
Zhang et al. Multifunctional polyethylene glycol (PEG)-poly (lactic-co-glycolic acid)(PLGA)-based nanoparticles loading doxorubicin and tetrahydrocurcumin for combined chemoradiotherapy of glioma
JP7164205B2 (ja) キナ酸修飾ナノ粒子およびその使用
Hyldbakk et al. Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
Wang et al. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer
Zhang et al. Tumor-targeting micelles based on linear–dendritic PEG–PTX8 conjugate for triple negative breast cancer therapy
Zhu et al. Delivery of acetylthevetin B, an antitumor cardiac glycoside, using polymeric micelles for enhanced therapeutic efficacy against lung cancer cells
Kazemi et al. In vitro and in vivo evaluation of novel DTX-loaded multifunctional heparin-based polymeric micelles targeting folate receptors and endosomes
Enteshari et al. Antitumor activity of raloxifene-targeted poly (styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice
Jin et al. Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles
Santini et al. Intravenous and intratumoral injection of Pluronic P94: The effect of administration route on biodistribution and tumor retention
Zhao et al. A’stealth’gene delivery system targeting hepatic stellate cells for the treatment of liver fibrosis
Han et al. Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles
US12433846B2 (en) Drug delivery system for treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230718

R150 Certificate of patent or registration of utility model

Ref document number: 7317038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250